Abstract
The recombinant human granulocyte colony-stimulating factor (G-CSF) known as filgrastim (Tevagrastim(®), Ratiograstim(®), Biograstim(®)) in Europe (approved in 2008) and tbo-filgrastim (Granix(®)) in the USA (approved in 2012; Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel) is indicated to reduce the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. This article presents pooled clinical data for tbo-filgrastim compared with Neupogen(®) (Amgen, Thousand Oaks, CA, USA) as well as tbo-filgrastim post-marketing safety data. The safety and efficacy of tbo-filgrastim were evaluated in three phase III studies in 677 patients receiving myelosuppressive chemotherapy and study drug (348 patients with breast cancer, 237 with lung cancer, 92 with non-Hodgkin lymphoma). In each study, the efficacy of tbo-filgrastim was similar to that of Neupogen. Overall, 633 (93.5 %) patients receiving the study drug experienced 6093 treatment-emergent adverse events (AEs), most of which were related to chemotherapy. Adverse events related to the study drug (tbo-filgrastim or Neupogen) were experienced b...Continue Reading
References
Jul 18, 1991·The New England Journal of Medicine·J CrawfordG Rausch
Jun 2, 1988·The New England Journal of Medicine·J L GabriloveLawrence Souza
Oct 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G MorstynK Alton
Feb 1, 1966·Annals of Internal Medicine·G P BodeyE J Freireich
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V Trillet-LenoirD Tomita
Jun 23, 1999·Transfusion·P AnderliniM Körbling
Dec 17, 2002·Annals of Hematology·D W BeelenU W Schaefer
Apr 19, 2003·Transfusion·David StroncekSusan F Leitman
Jan 13, 2004·Cancer·Jeffrey CrawfordGary H Lyman
May 14, 2005·Journal of Clinical Apheresis·Massimo MartinoFortunato Morabito
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas J SmithAntonio C Wolff
Feb 6, 2007·The American Journal of Emergency Medicine·Nicole J WatringJames J Stark
Mar 6, 2007·Journal of the National Comprehensive Cancer Network : JNCCN·Jeffrey CrawfordUNKNOWN National Comprehensive Cancer Network (NCCN)
Jun 15, 2007·Bone Marrow Transplantation·C C TigueC L Bennett
Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicole M KudererGary H Lyman
Mar 5, 2008·Current Oncology·C T KouroukisJ Mikhael
Nov 19, 2008·BMC Cancer·A del GiglioH Lubenau
Dec 26, 2008·Cases Journal·Nehal MasoodRomana Idress
Apr 7, 2009·Leukemia & Lymphoma·A EngertA del Giglio
May 1, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ulrich GatzemeierAuro Del Giglio
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J CrawfordUNKNOWN ESMO Guidelines Working Group
Nov 26, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproUNKNOWN European Organisation for Research and Treatment of Cancer
Feb 20, 2013·Expert Opinion on Drug Safety·Ivo AbrahamKaren MacDonald
Citations
Mar 30, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Hannah A Blair, Lesley J Scott
Aug 13, 2017·Targeted Oncology·Lee S RosenRonald L Burkes
Nov 18, 2018·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Camille N AbboudAshutosh Pathak
Aug 4, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Jamal ZekriAhmed Allithy